Monotherapy Option for Type 2 Diabetes Patients : Muraglitazar effectively lowered hemoglobin A_1c and triglycerides while raising HDL cholesterol levels.

There were no confirmed cases of glucose values at or below 50 mg/dL, and no patient dropped out of the study due to hypoglycemia. Mean change in body weight from baseline were gains of 1.1 kg in the 2.5-mg muraglitazar group and 2.1 kg with 5.0 mg, while the placebo group lost a mean of 0.8 kg. The open-label patients gained 2.9 kg.

Adverse events led to discontinuation of the study in 3%–4% of all muraglitazar groups and the placebo group, while rates of discontinuation due to lack of efficacy in the double-blind patients were 8% for 2.5 mg and 6% for 5.0 mg, compared with 23% for placebo.